CurveBeam AI Ltd. engages in the research, design, and manufacture of cone beam computed tomography imaging systems. The company is headquartered in Hatfield, Pennsylvania. The company went IPO on 2023-08-23. The Company’s orthopedic products include HiRise, LineUP, pedCAT Premium, pedCAT, InReach, and CubeVue Software. Its bone health products include InReach HR-pQCT, and OSSView. Its systems can be utilized across multiple locations via a mobile imaging solution that is self-contained and easy to operate. HiRise is a bilateral, weight bearing CT imaging of the entire lower extremities including hips/pelvis, distal upper extremities. LineUP is a bilateral, weight bearing CT imaging of the distal lower extremities and distal upper extremities. InReach HR-pQCT is a high resolution peripheral quantitative CT (HR-pQCT) imaging system designed for the point-of-care.
Follow-Up Questions
What is Curvebeam AI Ltd (CRVAF)'s P/E Ratio?
The P/E ratio of Curvebeam AI Ltd is N/A
What is the price performance of CRVAF stock?
The current price of CRVAF is 0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Curvebeam AI Ltd?
Curvebeam AI Ltd belongs to Health Care industry and the sector is Health Care
What is Curvebeam AI Ltd market cap?
Curvebeam AI Ltd's current market cap is $0
Is Curvebeam AI Ltd a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Curvebeam AI Ltd, including 1 strong buy, 3 buy, 1 hold, 0 sell, and 1 strong sell
